drugset
Drugs / SM17
last change Mar 2026 re-read 3 minutes ago

SM17

Monoclonal antibody targets IL17RB via inhibition

Developed for
atopic eczema · asthma
Investigated by
SinoMab BioScience Ltd

Trials 4

today NCT07445919 · Ph 2 NCT07466940 · Ph 1 NCT07103369 · Ph 1 NCT05332834 · Ph 1
20232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 13 trials · 1 met primary
Phase 1 NCT07466940 Oct 2025 → Feb 2026 asthma, atopic eczema, inflammatory bowel disease SinoMab BioScience Ltd Completed No outcome recorded
Phase 1 NCT07103369 Nov 2023 → Mar 2025 atopic eczema SinoMab BioScience Ltd Completed Met primary
Phase 1 NCT05332834 Jun 2022 → Sep 2023 asthma SinoMab BioScience Ltd Completed No outcome recorded
Phase 21 trial
Phase 2 NCT07445919 Mar 2026 → Apr 2027 expected atopic eczema SinoMab BioScience Ltd Recruiting No outcome recorded

News releases announcing trial results or a regulatory action · 10

DateIssuerRelease
2026-02-23 SinoMab BioScience Ltd Results SinoMab (03681.HK) Publishes Preclinical Studies for SM17 in ERJ Open Research, Highlighting Strong Therapeutic Potential in CRSwNP and IPF Treatment sinomab.com ↗
SinoMab BioScience Limited (“SinoMab” or the “Company”, Stock Code: 3681.HK), is pleased to announce that the preclinical data for SM17, a first-in-class anti-IL-17RB antibody has been published in ERJ Open Research , which demonstrates that SM17 significantly ameliorates pathological features in chronic rhinosinusitis with nasal polyps (CR SwNP) and idiopathic pulmonary fibrosis (IPF) via dual suppression of Th2/Th17 pathways and anti-fibrotic activity, supporting its potential as a transformative therapy.
2025-12-11 SinoMab BioScience Ltd Regulatory SinoMab (03681.HK) Achieves Key Regulatory Milestone as NMPA Accepts IND Application for SM17, a Novel IL-25 Receptor AnƟbody for Inflammatory Bowel Disease sinomab.com ↗
SinoMab (03681.HK) Achieves Key Regulatory Milestone as NMPA Accepts IND ApplicaƟon for SM17, a Novel IL-25 Receptor AnƟbody for Inflammatory Bowel Disease
2025-04-09 SinoMab BioScience Ltd Results Breakthrough Phase 1b POC Results for SM17 in Atopic Dermatitis Potentially a First-and Best-in-Class Product, Combining Deep Pruritus Relief, Effective Skin Clearance, and a Well-tolerated Safety Profile sinomab.com ↗
2024-12-12 SinoMab BioScience Ltd Results Results from Pre-clinical Models and Phase I Clinical Study of SinoMab SM17 on Asthma Had Been Published on Frontiers in Immunology sinomab.com ↗
2024-04-16 SinoMab BioScience Ltd Results Preclinical results of SM17 on atopic dermatitis (AD) published on International Scientific Journal Allergy Confirmed that the therapeutic efficacy of SM17 for treating AD is comparable to that of JAK1 inhibitor with good tolerability and safety sinomab.com ↗
The publication in this international, peer-reviewed and well-cited journal Allergy establishes the scientific validity of SM17 on the treatment of AD, and highlights the potential of SM17 as a revolutionary product in this field.
2023-09-11 SinoMab BioScience Ltd Regulatory SinoMab’s IND Application of SM17 has once again Received Approval from NAMP Clinical Development Program for the Treatment of AD to be Initiated Shortly sinomab.com ↗
2023-08-14 SinoMab BioScience Ltd Regulatory SinoMab Announces that IND Application of SM17 for the Treatment of Asthma was Approved by NAMP Speeding up Domestic Clinical Trials sinomab.com ↗
2023-06-12 SinoMab BioScience Ltd Regulatory SinoMab Submits another IND Application for SM17 for the Treatment of Atopic Dermatitis, Which was Accepted by NMPA CDE sinomab.com ↗
2023-05-22 SinoMab BioScience Ltd Regulatory SinoMab Annouces IND Application of SM17 for the Treatment of Asthma was Accepted by NMPA CDE sinomab.com ↗
2022-03-14 SinoMab BioScience Ltd Regulatory IND Application for SinoMab's First-in-Class Asthma Therapeutic Product SM17 Approved by FDA sinomab.com ↗

All press releases naming this drug 13 releases

DateIssuerRelease

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 5 sources stand behind the page.

FieldValueCited text
Known as SM17 ClinicalTrials.gov intervention name — accepted as the source's own label NCT07103369 ↗
3

NCT07445919 ↗

NCT07466940 ↗

NCT05332834 ↗
Action Inhibit “the blockage of IL-17RB via SM17” PMID 39717777 ↗ Dec 2024
Modality Monoclonal antibody “SM17, a novel humanized monoclonal antibody” PMID 39717777 ↗ Dec 2024
Route Intravenous “The safety, pharmacokinectics (PK), pharmacodynamics (PD), and immunogenicity of intravenous (IV) doses of SM17 were assessed” PMID 39717777 ↗ Dec 2024
Target IL17RB “blockage of IL-17RB via SM17” PMID 39717777 ↗ Dec 2024